“In the Know” features conversations with the people and personalities in biopharma.

Azita Saleki-Gerhardt is used to simultaneously navigating divergent cultures. At the University of Wisconsin, she slowly adapted to American life while struggling to dispel her fellow students’ stereotypes about Iran, her home country. After earning a doctorate in pharmaceutics, she spent the 1990s as a scientist developing and tweaking drug formulas in Abbott’s labs, and later overseeing technical aspects of the company’s manufacturing process.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Here are the cardinal rules for scientists presenting to CEO’s:

    1) CEOs are optimists by nature.
    2) their mind is 95% made up before you enter the room.
    3) your job is to “close the deal”.
    4) forget about fair and balanced.
    5) the probability of success is always 95%.

    You may as well be optimistic since it’s your neck that will be first on the chopping block when your studies fail.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy